New York State Teachers Retirement System Lowers Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

New York State Teachers Retirement System decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,030 shares of the specialty pharmaceutical company’s stock after selling 400 shares during the period. New York State Teachers Retirement System’s holdings in Collegium Pharmaceutical were worth $581,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of COLL. Gladius Capital Management LP purchased a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth approximately $32,000. nVerses Capital LLC lifted its holdings in Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 1,600 shares during the period. GAMMA Investing LLC boosted its position in Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC grew its stake in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the period. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at $204,000.

Collegium Pharmaceutical Trading Down 7.3 %

NASDAQ COLL opened at $32.16 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock’s 50-day simple moving average is $37.07 and its two-hundred day simple moving average is $35.21. Collegium Pharmaceutical, Inc. has a twelve month low of $23.44 and a twelve month high of $42.29. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 13.86 and a beta of 0.95.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.13 EPS. Research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on COLL shares. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. HC Wainwright raised their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, Truist Financial upped their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.